V4640

Sigma-Aldrich

VU0357017 monohydrochloride

≥98% (HPLC)

Sinónimos:
CID 25010775, ML071 hydrochloride, 4-[[2-[(2-Methylbenzoyl)amino]ethyl]amino]-1-piperidinecarboxylic acid ethyl ester monohydrochloride, SID 56353039
Empirical Formula (Hill Notation):
C18H27N3O3 · HCl
Número de CAS:
Peso molecular:
369.89
MDL number:
PubChem Substance ID:
NACRES:
NA.77

Quality Level

assay

≥98% (HPLC)

form

powder

color

white to off-white

solubility

DMSO: ≥10 mg/mL

storage temp.

2-8°C

SMILES string

Cl.CCOC(=O)N1CCC(CC1)NCCNC(=O)c2ccccc2C

InChI

1S/C18H27N3O3.ClH/c1-3-24-18(23)21-12-8-15(9-13-21)19-10-11-20-17(22)16-7-5-4-6-14(16)2;/h4-7,15,19H,3,8-13H2,1-2H3,(H,20,22);1H

InChI key

XKJQVUIXSBOCPP-UHFFFAOYSA-N

Packaging

5, 25 mg in glass bottle

Biochem/physiol Actions

VU0357017 is a subtype-selective M1 muscarinic acetylcholine allosteric agonist. VU0357017 has a potency of 200 nM and Achmax of 81% and had no activity at M2-M5 up to the highest concentrations tested and also had little or no detectable antagonist activity at any other mAChR subtype at concentrations over 2 orders of magnitude higher than those required to activate M1 or activity at a large panel of GPCRs, ion channels, and transporters. In contrast, TBPB inhibited responses to ACh at each of the other mAChR subtypes. VU0357017 was active in reversing cognitive deficits induced by scopolamine in a preclinical rodent model.

RIDADR

NONH for all modes of transport

WGK Germany

WGK 2

Flash Point F

Not applicable

Flash Point C

Not applicable

Certificado de Análisis

Certificado de origen

Andrew P Bacon et al.
PloS one, 8(9), e73182-e73182 (2013-09-26)
Endurance exercise training studies frequently show modest changes in VO2max with training and very limited responses in some subjects. By contrast, studies using interval training (IT) or combined IT and continuous training (CT) have reported mean increases in VO2max of...
Donghyun Jee et al.
Investigative ophthalmology & visual science, 54(10), 6827-6833 (2013-09-26)
We evaluated the prevalence and risk factors for diabetic retinopathy (DR) in a representative Korean population. This cross-sectional study involved 16,109 subjects aged >40 years who had participated in the Korean National Health and Nutrition Survey from 2008 to 2011....
Suzette Glasner-Edwards et al.
Journal of dual diagnosis, 9(2), 123-128 (2013-09-26)
Although trauma is a well-established risk factor for substance use disorders, little is known about the association between posttraumatic stress disorder (PTSD) and treatment outcomes among methamphetamine users. In the present study, we examine the relationship between PTSD and post-treatment...
Tannistha Nandi et al.
mBio, 4(5), e00709-e00713 (2013-09-26)
The Gram-negative bacterium Burkholderia pseudomallei is the causative agent of melioidosis, a serious infectious disease of humans and animals. Once considered an esoteric tropical disease confined to Southeast Asia and northern Australia, research on B. pseudomallei has recently gained global...
Ravi Parasuraman et al.
Case reports in transplantation, 2013, 969186-969186 (2013-09-26)
Adenoviruses (AdV) are emerging pathogens with a prevalence of 11% viruria and 6.5% viremia in kidney transplant recipients. Although AdV infection is common, interstitial nephritis (ADVIN) is rare with only 13 biopsy proven cases reported in the literature. We report...
Artículos
Muscarinic acetylcholine receptors are G protein-coupled receptors (GPCRs) and mediate acetylcholine actions in the CNS and non-nervous tissues. Learn more about acetylcholine receptors and their role in cell signaling.
Más información

Nuestro equipo de científicos tiene experiencia en todas las áreas de investigación: Ciencias de la vida, Ciencia de los materiales, Síntesis química, Cromatografía, Analítica y muchas otras.

Póngase en contacto con el Servicio técnico

Redes sociales

LinkedIn icon
Twitter icon
Facebook Icon
Instagram Icon

Merck

Investigación. Desarrollo. Producción.

Somos un proveedor líder para la industria de Ciencias de la Vida con soluciones y servicios para investigación, desarrollo y producción biotecnológicos, y para desarrollo y producción de tratamientos farmacéuticos

© 2021 Merck KGaA, Darmstadt, Alemania y/o sus filiales. Todos los derechos reservados.

Queda estrictamente prohibida la reproducción sin permiso de cualquiera de los materiales de la página web.